TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Premenopausal female, between 18 and 49 years of age, inclusive, at the time of signing consent.~2. Clinical diagnosis of endometriosis (laparoscopy or laparotomy) performed within 10 years of entry into the Washout Period.~3. Agrees to use required birth control methods during the entire length of participation in the study.~4. Subject has a Composite Pelvic Signs and Symptoms Score total score of 6 or greater at Screening with a score of at least 2 for dysmenorrhea AND at least 2 for non-menstrual pelvic pain.~5. Subjects must have at least two regular menstrual cycles with an interval of 24-38 days within the Screening Period, prior to Day 1.~Exclusion Criteria:~1. Subject is pregnant or breast feeding or is planning a pregnancy within the next 24 months or is less than 6 months postpartum, post-abortion, or post-pregnancy at the time of entry into the Screening Period.~2. Subject has a history of previous non-response to gonadotropin-releasing hormone (GnRH) agonists, GnRH antagonists, Depot medroxyprogesterone acetate, or aromatase inhibitors as assessed by subject report of no improvement in dysmenorrhea or non-menstrual pelvic pain.~3. Subject has chronic pelvic pain that is not caused by endometriosis that requires chronic analgesic or other chronic therapy, or that would interfere with the assessment of endometriosis related pain.~4. Clinically significant gynecologic condition identified on Screening transvaginal ultrasound or endometrial biopsy.~5. Subject has a history of osteoporosis or other metabolic bone disease.~6. Subject has a current history of undiagnosed abnormal uterine bleeding.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo twice daily (BID) for the 6-month Treatment Period
- Elagolix 150 mg QD (Type: EXPERIMENTAL): Elagolix 150 mg once daily (QD) for the 6-month Treatment Period
- Elagolix 200 mg BID (Type: EXPERIMENTAL): Elagolix 200 mg BID for the 6-month Treatment Period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* patients having H. pylori related chronic gastritis with/without peptic ulcers who are aged greater than 18 years and are willing to received eradication therapy.~Exclusion Criteria:~* pregnant or nursing woman~* serious concomitant illness and malignant tumor of any kind~* history of hypersensitivity to test drugs~* serious bleeding during the course of this ulcer~* previous gastric surgery~* receiving bismuth salts, proton pump inhibitors, or antibiotics in the previous month.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- high dose dual therapy (Type: EXPERIMENTAL): group A1 and A2 - high dose dual therapy (rabeprazole 20 mg qid, amoxicillin 750 mg qid for 14 days)
- sequential therapy (Type: EXPERIMENTAL): group B1 and B2 - sequential therapy (rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days)
- clarithromycin-based triple therapy (Type: ACTIVE_COMPARATOR): group C1 - clarithromycin-based triple therapy (rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days)
- levofloxacin-based triple therapy (Type: ACTIVE_COMPARATOR): group C2 - levofloxacin-based triple therapy (rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Unrestricted Diet for Screening Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals on the early colorectal cancer detection program who agreed to undergo colonoscopy after positive results on the fecal immunochemical test (FIT)~Exclusion Criteria:~* Individuals in which colonoscopy, cleansing solution or bisacodyl are contraindicated~* Subjects that are considered to have a linguistic barrier or to be unable to understand the instructions and / or give informed consent.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Unrestricted diet (Type: EXPERIMENTAL): The participant is not instructed to follow any dietary recommendation before colonoscopy. But only the restriction and fasting required for sedation.
- One day low residue diet (Type: ACTIVE_COMPARATOR): The participant is instructed to follow a low residue diet the day before the colonoscopy.~It will be given a informative document and educated by a nurse.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Participants with heterozygous familial hypercholesterolemia or non-familial hypercholesterolemia who were not adequately controlled with a stable daily dose of statin with or without other lipid modifying therapy, at stable dose prior to the screening visit (Week -3).~Exclusion criteria:~1. LDL-C \<100 mg/dL (\<2.59 mmol/L) at the screening visit in participants with heterozygous familial hypercholesterolemia or in participants with non-familial hypercholesterolemia who had a history of documented coronary heart disease as described in Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.~2. LDL-C \<120 mg/dL (\<3.10 mmol/L) at the screening visit in participants with non-familial hypercholesterolemia who had a history of documented diseases or other risk factors as categorized in primary prevention category III as described in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.~3. Not on a stable daily dose of lipid modifying therapy (including statin) within 4 weeks prior to the screening visit or between screening and randomization visits.~4. Age \<20 years at the screening visit.~The above information is not intended to contain all considerations relevant to a participants' potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Q2W (Type: PLACEBO_COMPARATOR): Placebo (for alirocumab) every two weeks (Q2W) added to stable lipid-modifying therapy (LMT).
- Alirocumab 75 mg/Up to 150 mg Q2W (Type: EXPERIMENTAL): Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels above pre-specified threshold at Week 8 as defined in Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012 i.e.~* ≥100 mg/dL (2.59 mmol/L) in heFH participants or in non-familial hypercholesterolemia (non-FH) participants who had a history of documented coronary heart disease (CHD)~* ≥120 mg/dL (3.10 mmol/L) in non-FH participants who had a history of documented diseases or other risk factors as categorized in primary prevention category III

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Atorvastatin in Graves' Orbitopathy (GO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
1. Informed consent~2. A diagnosis of Graves' disease~3. A moderately severe GO~4. Active GO~5. No corticosteroids or immunosuppressive treatment for GO in the last 3 months.~6. No previous surgical treatment for GO~7. No contraindication to GC~8. Male and female patients of age: 18-75 years~9. LDL-cholesterol levels of 115-189 mg/dl~10. No more than one cardiovascular risk factor (diabetes, high blood pressure, smoking, familial history of acute cardiovascular events, obesity)~11. Effective method of contraception~12. No mental illness that prevent patients from comprehensive, written informed consent~13. Compliant patient, regular follow-up possible~Exclusion Criteria:~1. lack of informed consent~2. Absence of Graves' hyperthyroidism (present or past)~3. Inactive GO~4. Optic neuropathy~5. Corticosteroids or immunosuppressive treatment for GO in the last 3 months.~6. Previous surgical treatment for GO~7. Contraindications to GC~8. Pregnancy, breast-feeding women~9. Acute or chronic liver disease~10. Hypersensitivity to atorvastatin or other statins, or hypersensitivity or intolerance to the medication excipients such as lactose.~11. Medications interfering/interacting with statins (CYP3A4 inhibitors or inductors)~12. Relevant Malignancy~13. Corticosteroids or other immunosuppressive agents within last 3 months~14. Recent (≤1 year) history of alcoholism or drug abuse~15. Clinical ASCVD (AthroSclerotic CardioVascular Disease)~16. LDL-cholesterol levels ≥190 mg/dl or presence of more than one associated cardiovascular risk factor (diabetes, high blood pressure, smoking, familial history of acute cardiovascular events, obesity)~17. Severe familial hyperlipemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Statins (Type: EXPERIMENTAL): Atorvastatin 20 mg daily associated with intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
- No statins (Type: ACTIVE_COMPARATOR): Intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed TCC of the urothelial tract (bladder, renal pelvis, or ureter)~2. Prior exposure to gemcitabine-platinum regimen as either adjuvant or palliative chemotherapy.~3. Unidimensionally measurable disease outside prior radiotherapy ports~4. Age 18 years or older~5. ECOG performance status of 0\~2~6. Life expectancy of at least 3 months~7. Adequate BM function (ANC \>1,500/mm3 \& Platelet \>100,000/mm3)~8. Adequate hepatic function (Bilirubin no greater than 2 times upper limit of normal (ULN) \& AST or ALT no greater than 2.5 times ULN), and renal function (creatinine \<1.5 X times ULN)~9. No pre-existing clinically significant grade 2 or greater neuropathy~Exclusion Criteria:~1. Pregnant or lactating patients~2. Presence or history of CNS metastasis~3. Patients with prior RT to the axial skeleton within 4 weeks of chemotherapy start to greater than 25% of bone marrow~4. Any preexisting medical condition of sufficient severity to prevent full compliance with the study, including active infection, active cardiac symptoms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Genexol PM (Type: EXPERIMENTAL): Genexol PM intravenous infusion every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin Treatment for Trigger Points

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who diagnosed fibromyalgia syndrome,~* Patients who were also diagnosed as cervical myofascial pain syndrome based on the upper trapezius muscle~Exclusion Criteria:~* Patients who had received dry needling or local anesthetic injection to trigger point in the dominant upper trapezius muscle within 3 months of the start of the study.~* renal insufficiency,~* impaired liver function,~* malignancy,~* pregnancy~* infections,~* history of drug or alcohol abuse

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Patients received pregabalin (target dose 300 mg/day) and exercise therapy (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months
- Group 2 (Type: NO_INTERVENTION): Patients received exercise therapy alone (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients prostatectomised (PT) due to histologically verified adenocarcinoma of the prostate gland who currently are not being treated, or expected within the next 8 months to be treated, with any anti-cancer treatment.~* ECOG performance status 0 or 1.~Exclusion Criteria:~* Patient has been treated with Androgen Deprivation Therapy (ADT), or expected to receive such treatment within the next 8 months from enrolment.~* Severe medical conditions, such as but not limited to severe asthma/chronic obstructive pulmonary disease (COPD), New York Heart Association (NYHA) grading 3 or above, poorly regulated insulin dependent diabetes, any significant organ damage as judged by the Investigator.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RV001V (Type: EXPERIMENTAL): RV001 Vaccine 0.1 mg/mL (RV001V). RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women 18-65 years~* \>50 mf/ml in finger stick blood samples~* Willing to give informed consent~Exclusion Criteria:~* Prior treatment for LF within last 5 years~* Pregnant (do pregnancy test)~* Hemoglobin \< 7 g/dl~* permanent disability, serious medical illness that prevents or impedes study participation and/or comprehension~* AST/ALT and creatinine \> 1.5 upper limit of normal.~* Urine dipstick with glucose ≥ 2+ and/or protein ≥ 2+

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- standard treatment (Type: ACTIVE_COMPARATOR): Diethylcarbamazine 6 mg/kg + Albendazole 400 mg administered annually (at 0, 12, and 24 months).
- DEC 6 mg/kg + Alb 400 mg x 1 (Type: EXPERIMENTAL): Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once
- DEC + ALB + IVM (Type: EXPERIMENTAL): Diethylcarbamazine 6 mg/kg + Albendazole 400 mg + Ivermectin 200 µg/kg administered once only at the beginning of the RCT (0 month)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Age \>18~* Able to provide written informed consent and willing to participate in all required study follow-up assessments~* Symptomatic CAD with refractory angina defined as CCS class II to IV, despite optimal tolerated medical therapy~* Abnormal coronary microvascular function indices: CFR≤2.5 and/or IMR≥25~Exclusion Criteria~* Recent (within 3 months) acute coronary syndrome~* Patients with prior coronary artery bypass surgery~* Unstable angina (recent onset angina, crescendo angina, or rest angina with ECG changes) during the last 30 days~* Subjects in cardiogenic shock (systolic pressure \< 80mm/Hg, on vasopressors or intraaortic counter pulsation) at the time of consenting. Subjects who recover from cardiogenic shock by the time of consenting are eligible.~* Obstructive CAD on coronary angiography (\>70% stenosis or 50-70% stenosis with iFR\<0.89 or FFR\<0.8 in epicardial artery)~* Inability to perform invasive coronary flow evaluation and/or measure CFR and IMR in the LAD~* Severe valvular heart disease~* LVEF\<30%~* Decompensated congestive heart failure (CHF) or hospitalization due to CHF during the last 3 months~* Patient with a pacemaker electrode in the CS~* Mean right atrial pressure \>15 mmHg~* Anomalous or abnormal CS anatomy (e.g., tortuosity, aberrant branch, persistent left superior vena cava (SVC) as demonstrated on angiogram~* CS diameter at the site of planned implantation greater than 13mm or less than 9.5 mm as measured by angiogram~* Severe chronic obstructive pulmonary disease (COPD) indicated by a forced expiratory volume in one second that is less than 55 percent of the predicted value~* Tricuspid valve replacement or repair (tissue or mechanical)~* Chronic renal failure (serum creatinine \>2mg/dL), and or on chronic hemodialysis~* Moribund, or with comorbidities limiting life expectancy to less than one year~* Known severe reaction to required procedural medication~* Known allergy to stainless steel or nickel~* Magnetic Resonance Imaging (MRI) within 8 weeks of Reducer implantation~* Participation in another ongoing investigational trial~* Additional factors deemed unsuitable for trial enrollment per discretion of principal investigator~* Inmates

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chronic Refractory Angina (Type: EXPERIMENTAL): Subjects with chronic refractory angina will undergo implantation of the Neovasc Reducer™ System in the cardiac catheterization laboratory.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Houtou Jianweiling Tablet in the Treatment of Chronic Non-Atrophic Gastritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* (1) Comply with the diagnostic criteria for chronic non-atrophic gastritis.~* (2) Age between 18 to 65 years.~* (3) Voluntarily participate the clinical trials and sign informed consent.~Exclusion Criteria:~* (1) Subjects with history of gastric surgery.~* (2) Patients with complicated and special types of gastritis, peptic ulcer, hemorrhage, cholecystitis, cholelithiasis, dysplasia of gastric mucosa or pathological diagnosis of suspected malignant change.~* (3) Patients with atrophy and/or intestinal metaplasia through pathological examination showed;.~* (4) Severe primary diseases associated with cardiovascular, cerebrovascular, lung, liver, kidney and hematopoietic system (above grade II of cardiac function; Cr value above the upper limit of normal value), or serious diseases affecting their survival, such as cancer or AIDS;~* (5) Patients who have used Chinese and Western medicine to treat chronic non-atrophic gastritis in the last two weeks;~* (6) Subjects with psychiatric disorders or a history of alcohol/drug abuse;~* (7) Pregnant women, woman who are preparing for pregnancy, lactating women;~* (8) Patients who are allergic constitution or allergic to known ingredients of test drugs;~* (9) Those who have participated in or are participating in other drug clinical trials in the past 3 months;~* (10) The syndrome differentiation is not clear or there are too many and complicated syndromes for the subjects;~* (11) Subjects that researchers do not consider appropriate to participate in clinical trials.~* (12) Patients with poor compliance are not allowed to participate in this trial.~  * Those who meet one or more of the above exclusion criteria cannot be included in the clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Test group (Houtou Jianeweiling tablet ) (Type: EXPERIMENTAL): Houtou Jianweiling tablet (0.38 g), 4 tablets taken orally at a time, 3 times a day and Omeprazole Enteric-coated placebo tablet, taken 1 tablet orally once a day before breakfast.
- Control group (Omeprazole enteric-coated tablet) (Type: ACTIVE_COMPARATOR): Omeprazole Enteric-coated tablet (20 mg), 1 tablet taken orally once a day before breakfast and Houtou Jianweiling placebo tablets, taken orally, 4 tablets at a time, 3 times a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete